Stern, M.; Herrmann, R. (2005). “Overview of monoclonal antibodies in cancer therapy: present and promise”. Critical Reviews in Oncology/Hematology54 (1): 11–29. doi:10.1016/j.critrevonc.2004.10.011. PMID15780905.
Tabrizi, M.; Tseng, C.; Roskos, L. (2006). “Elimination mechanisms of therapeutic monoclonal antibodies”. Drug Discovery Today11 (1–2): 81–88. doi:10.1016/S1359-6446(05)03638-X. PMID16478695.
Lordick, F; Ott, K; Weitz, J; Jäger, D (2008). “The evolving role of catumaxomab in gastric cancer”. Expert Opinion on Biological Therapy8 (9): 1407–15. doi:10.1517/14712598.8.9.1407. PMID18694358.
Miyasaka, N (2009). “Adalimumab for the treatment of rheumatoid arthritis”. Expert Review of Clinical Immunology5 (1): 19–22. doi:10.1586/1744666X.5.1.19. PMID20476896.
Stern, M.; Herrmann, R. (2005). “Overview of monoclonal antibodies in cancer therapy: present and promise”. Critical Reviews in Oncology/Hematology54 (1): 11–29. doi:10.1016/j.critrevonc.2004.10.011. PMID15780905.
Tabrizi, M.; Tseng, C.; Roskos, L. (2006). “Elimination mechanisms of therapeutic monoclonal antibodies”. Drug Discovery Today11 (1–2): 81–88. doi:10.1016/S1359-6446(05)03638-X. PMID16478695.
Lordick, F; Ott, K; Weitz, J; Jäger, D (2008). “The evolving role of catumaxomab in gastric cancer”. Expert Opinion on Biological Therapy8 (9): 1407–15. doi:10.1517/14712598.8.9.1407. PMID18694358.
Miyasaka, N (2009). “Adalimumab for the treatment of rheumatoid arthritis”. Expert Review of Clinical Immunology5 (1): 19–22. doi:10.1586/1744666X.5.1.19. PMID20476896.